MERCK MEDICAID PROPOSAL ACCEPTED BY UTAH; DELAWARE, SOUTH CAROLINA MAY BE NEXT
Utah's state Medicaid agency reportedly has accepted Merck's legislative proposal to obtain prescription drug price discounts in exchange for open access to Merck products. Arkansas, which like Utah has an open formulary, already has accepted Merck's proposal ("The Pink Sheet" May 7, p. 3). In addition, the company says that Delaware and South Carolina "seem certain" to accept the offer. Utah accepted the proposal under two conditions, which were agreed to by Merck. The state did not want to sign a contract that bound its Medicaid agency to keeping an open formulary for all Merck products in perpetuity. The state also wanted to maintain a prior approval constraint on Pepcid prescriptions; Utah was concerned that physicians may order therapeutic doses for patients who need only maintenance doses. Merck reportedly accepted the dosing constraint because it is not more restrictive than the FDA-approved label recommendation. Merck Sharp & Dohme President John Zabriskie told "The Pink Sheet" that although the company is "still in discussion" with most states," it is "hopeful that as many as 40 states" will accept the proposal by mid-summer. About 25 of those states currently have open formularies. Merck is particularly interested in having its offer accepted by those with restrictive formularies. About 13 states have formularies that are closed to Merck products, Zabriskie said. Another 12 restrict access to at least one Merck product -- for example, by requiring prior authorization. Of those 12, he added, at least six have indicated "strong interest" in the legislative proposal. Zabriskie contrasted Merck's proposal from the Medicaid bill sponsored by Sen. Pryor (D-Ark.). The Senate bill (S 2605) would "limit access" of Medicaid patients to prescription drugs, whereas the Merck proposal would "guarantee access." He maintained that, "socially and medically, government should be encouraging full access" to pharmaceuticals.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth